Key Highlights
● Twist Bioscience jumped on Friday, trading at about $165.19 compared with a previous close of $152.05.
● No company-specific catalyst accompanied the gain, and Jefferies had initiated coverage Thursday with a Hold rating and $150 target.
● Twist makes synthetic DNA, producing custom genes, DNA fragments and libraries used in drug discovery and diagnostics.
● Moderna jumped $28.00 to $225.00 and Ginkgo Bioworks, 10x Genomics and Illumina also rose in the biotech rally.
Twist Bioscience (NASDAQ:TWST) jumped on Friday, trading at about $165.19 compared with a previous close of $152.05. No company-specific catalyst accompanied the gain. Rather, the stock moved with a sweeping rally in biotech and life-science tools that lifted everything from Vaccine makers to genomics suppliers.
The only recent analyst news was mixed: A market report noted that Jefferies (NYSE:JEF) had initiated coverage of Twist on Thursday with a Hold rating and a price target of $150, below where the shares traded on Friday. That made the rally more a reflection of sector enthusiasm than a response to a fresh bullish call.
What Twist does
Twist Bioscience makes synthetic DNA. Using a silicon-based Manufacturing platform, it produces custom genes, DNA fragments and libraries that scientists use in drug discovery, antibody development, diagnostics and genetic sequencing. Its customers range from pharmaceutical giants to academic labs, which ties its fortunes to the health of biotech research spending.
With a Market Value of more than $9 billion, Twist is one of the larger listed names in synthetic biology, which gives its swings weight across the group. That positioning means Twist often trades as a proxy for the wider industry. When investors grow more optimistic about drug development, Demand for the tools behind that work tends to look brighter too.
The vaccine report and the biotech bid
Friday's optimism had a clear source. A media report said that the National Institutes of Health plans a public-private initiative, starting in December, to fast-track cancer-vaccine research, initially focusing on pancreatic, liver and colorectal cancers and some childhood tumors. Moderna (NASDAQ:MRNA) jumped $28.00 to $225.00, its highest close since 2021, and Novavax (NASDAQ:NVAX), BioNTech (NASDAQ:BNTX) and Vaxcyte (NASDAQ:PCVX) also rallied.
The buying spread to synthetic-biology and genomics names. Ginkgo Bioworks (NYSE:DNA) rose after saying it will provide access to its autonomous Boston lab for a National Science Foundation program, and some coverage also linked its move to the vaccine report. 10x Genomics (NASDAQ:TXG) and Illumina (NASDAQ:ILMN) climbed as well. Health care was among the S&P 500's strongest sectors on Friday and for the week.
Twist's gain also came after a period of weakness for many small and mid-sized growth stocks. The Russell 2000, a benchmark for smaller companies, rose 12.85 points to 2,806.98 on Friday but still recorded its fifth straight losing week.
The broader market
Stocks rose. The Nasdaq Composite gained 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54, about seven points below Tuesday's record close, and the Dow climbed 423.31 points to 51,654.95. Software and Cybersecurity rebounded strongly from Thursday's AI scare, while chipmakers lagged.
The macro picture remained a test for growth stocks. The 10-year Treasury Yield held near a 24-year high, the Fed raised rates in September for the first time since 2023, and Fed Governor Christopher Waller said: "The hikes do not need to come at consecutive meetings, but they should be in place in an acceptable period of time." Consumer sentiment slipped to a five-month low.
NIH Plan Details and Twist's Customer Demand Updates Are the Next Items to Watch
Monday, October 12 is Columbus Day, with stocks open and bonds closed. September consumer prices arrive Wednesday, October 14, followed by producer prices and retail sales on Thursday. Bank Earnings run from October 13 to 16, and the Fed meets on October 27 and 28. Details on the NIH-linked plan ahead of its expected December start, and any update from Twist on customer demand, are next in focus.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...